May 09, 2022
BASEL, Switzerland, May 09, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced that Luca Santarelli, M.D., Ph.D., Founder and Chief Executive
Change | |
Volume |
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Copyright © VectivBio AG, 2022. All Rights Reserved.